22nd Century Group (NASDAQ: XXII), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through modern plant science, today announced its appointment of John J. Miller to direct the growth and achieve the full potential of the company’s reduced nicotine tobacco business. Miller brings more than 35 years of experience in the tobacco and consumer packaged goods industries and a demonstrated ability to attain a track record of success and superior commercial results. “We are absolutely delighted to welcome John Miller to our team,” said Jim Mish, chief executive officer of 22nd Century Group. “His significant hands-on expertise and insight in strategic planning, assessing and implementing strategic partnership opportunities, and leading sales and marketing efforts will be instrumental in accelerating revenue, profit and market share growth for the company. We look forward to John’s contributions to the success of the company’s launch of VLN(R), our reduced nicotine cigarettes with 95% less nicotine than conventional cigarettes, which is the first and only modified risk tobacco product (‘MRTP’) approved by the FDA.”
To view the full press release, visit https://ibn.fm/Chpay
About 22nd Century Group Inc.
22nd Century Group is a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science. With dozens of patents allowing it to control nicotine biosynthesis in the tobacco plant, the company has developed proprietary reduced nicotine content (“RNC”) tobacco plants and cigarettes, which have become the cornerstone of the FDA’s comprehensive plan to address the widespread death and disease caused by smoking. The company received the first and only FDA MRTP authorization of a combustible cigarette in December 2021. In tobacco, hemp/cannabis, and hop plants, 22nd Century uses modern plant-breeding technologies, including genetic engineering, gene-editing and molecular breeding to deliver solutions for the life science and consumer products industries by creating new, proprietary plants with optimized alkaloid and flavonoid profiles as well as improved yields and valuable agronomic traits. For more information about the company, visit www.XXIICentury.com.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
